DNA copy number changes affecting TGF-β and PI3K-AKT signaling
| Type of change / localization . | Gene name . | Frequency . |
|---|---|---|
| Deletions of TGF-β pathway activators | ||
| 3q13.11-13.12 | CBLB | 4/73 (5%) |
| 9q31.1 | TGFBR1 | 2/73 (3%) |
| 12p13.2 | CDKN1B | 8/69 (12%) |
| 13q13.3 | SMAD9 | 1/73 (1%) |
| 18q21.1 | SMAD4 | 7/73 (10%) |
| Gains of TGF-β pathway inhibitors | ||
| 7q22.1 | SMURF1 | 5/73 (7%) |
| 17q23.3 | SMURF2 | 4/73 (5%) |
| Total number of affected T-ALL: 25/73 (34%) | ||
| Deletions of PI3K-AKT pathway inhibitors | ||
| 6q21 | FOXO3A | 5/73 (7%) |
| 10q23.31 | PTEN | 4/73 (5%) |
| Gains of PI3K-AKT pathway activators | ||
| 6q25.3 | IGF2R | 4/73 (5%) |
| 7p15.3 | IGF2BP3 | 2/73 (3%) |
| 11p15.5 | IGF2 | 4/72 (6%) |
| 14q32.33 | AKT1 | 2/73 (3%) |
| 15q26.3 | IGF1R | 1/73 (1%) |
| 17q23.2 | MSI2 | 4/73 (5%) |
| 17q21.2 | IGFBP4 | 3/73 (4%) |
| 17q24.1-24.2 | PRKCA | 4/72 (6%) |
| 19p13.3 | MKNK2 | 7/73 (10%) |
| 19q13.3 | IGFL4 | 3/73 (4%) |
| Total number of affected T-ALL: 21/73 (29%) |
| Type of change / localization . | Gene name . | Frequency . |
|---|---|---|
| Deletions of TGF-β pathway activators | ||
| 3q13.11-13.12 | CBLB | 4/73 (5%) |
| 9q31.1 | TGFBR1 | 2/73 (3%) |
| 12p13.2 | CDKN1B | 8/69 (12%) |
| 13q13.3 | SMAD9 | 1/73 (1%) |
| 18q21.1 | SMAD4 | 7/73 (10%) |
| Gains of TGF-β pathway inhibitors | ||
| 7q22.1 | SMURF1 | 5/73 (7%) |
| 17q23.3 | SMURF2 | 4/73 (5%) |
| Total number of affected T-ALL: 25/73 (34%) | ||
| Deletions of PI3K-AKT pathway inhibitors | ||
| 6q21 | FOXO3A | 5/73 (7%) |
| 10q23.31 | PTEN | 4/73 (5%) |
| Gains of PI3K-AKT pathway activators | ||
| 6q25.3 | IGF2R | 4/73 (5%) |
| 7p15.3 | IGF2BP3 | 2/73 (3%) |
| 11p15.5 | IGF2 | 4/72 (6%) |
| 14q32.33 | AKT1 | 2/73 (3%) |
| 15q26.3 | IGF1R | 1/73 (1%) |
| 17q23.2 | MSI2 | 4/73 (5%) |
| 17q21.2 | IGFBP4 | 3/73 (4%) |
| 17q24.1-24.2 | PRKCA | 4/72 (6%) |
| 19p13.3 | MKNK2 | 7/73 (10%) |
| 19q13.3 | IGFL4 | 3/73 (4%) |
| Total number of affected T-ALL: 21/73 (29%) |